RNA-Targeting Lends Renewed Focus to Gene Therapy Development Efforts

Video

Locanabio CEO James Burns, PhD, shares his outlook on the quickly changing landscape of gene therapy research.

No one can deny the lightning speed at which the gene and cell therapy space is advancing on a daily basis, but the ongoing evolution is particularly sweet for long-time industry players like James Burns, PhD, chief executive officer of Locanabio, Inc., a clinical-stage company focused on RNA-targeting gene therapies.

Locanabio recently presented new data at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, including an RNA-targeting CRISPR/Cas13d gene therapy approach for skipping USH2A exon 13 for the treatment of retinal disease, as well as preclinical in vivo data demonstrating safety and efficacy of their novel PUF RNA-binding protein system delivered via an adeno-associated virus serotype 9 (AAV9) vector in eliminating toxic CUG repeats in a mouse model of myotonic dystrophy type 1.

In an interview with GeneTherapyLive, Burns commented on the changing landscape of gene therapy research, adding a poignant reminder of why the field continues to push forward.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Rajeev Sivasankaran, PhD, vice president of neuroscience at Voyager Therapeutics
Sven Moller-Tank, PhD, a senior director at Regeneron
Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, codirector of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California
© 2025 MJH Life Sciences

All rights reserved.